Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company whose news flow centers on its sleep medicine franchise, led by LUMRYZ, and on significant corporate transactions. Company announcements repeatedly describe Avadel as focused on transforming medicines to transform lives, with a commercial emphasis on LUMRYZ, an FDA-approved, once-at-bedtime extended-release sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy.
News updates for AVDL commonly include clinical and regulatory milestones for LUMRYZ. Examples from recent press releases include completion of enrollment in REVITALYZ, a Phase 3 trial evaluating once-at-bedtime LUMRYZ as a potential treatment for idiopathic hypersomnia, and presentation of real-world REFRESH study data in narcolepsy. These items provide insight into Avadel’s efforts to expand the clinical evidence base and explore additional indications for its lead product, while clearly noting that LUMRYZ is only approved for narcolepsy.
Investors following AVDL news will also see frequent coverage of transaction-related developments. Avadel has announced a definitive agreement under which Alkermes plc will acquire the company via an Irish High Court–sanctioned scheme of arrangement, subsequent amendments to increase the offer, and shareholder approvals of the scheme. Additional news has covered an unsolicited proposal from H. Lundbeck A/S, the Avadel board’s evaluation of that proposal, and the board’s conclusions under the Irish Takeover Rules and the Alkermes Transaction Agreement.
Other recurring news themes include licensing and legal developments, such as Avadel’s exclusive global license for valiloxybate from XWPharma and a global settlement and license agreement with Jazz Pharmaceuticals relating to LUMRYZ and Jazz’s oxybate products. Together, these updates give readers a view into AVDL’s clinical pipeline, commercial performance, strategic partnerships and the progress of the Alkermes acquisition. For ongoing context on AVDL stock, this news page aggregates these company-issued announcements and related regulatory disclosures.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that its Board's Compensation Committee has approved inducement awards for twelve new employees. The awards consist of non-statutory options to purchase 131,700 ordinary shares under the company's 2021 Inducement Plan. These options come with a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary of each employee's start date and subsequent 25% portions vesting on the second, third, and fourth anniversaries. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced it will host a conference call and live webcast on January 8, 2025, at 4:30 p.m. ET to provide a corporate update and discuss preliminary unaudited financial results for Q4 and full-year 2024. The webcast will be accessible through the company's investor relations website section at www.avadel.com, where it will remain archived for 90 days after the event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Avadel Pharmaceuticals (Nasdaq: AVDL) published findings in Brain Sciences revealing significant challenges faced by narcolepsy patients using twice-nightly sodium oxybate therapy. The study combined social media analysis and survey results from 87 U.S. adults.
Key findings showed that 75.3% of respondents reported accidentally missing their second dose, with 37% missing it weekly or more often. Nearly three-fourths reported improper timing of their second dose, with 58.8% taking it too late and 21.2% too early. Notably, 31.8% experienced injuries after waking for their second dose.
The study highlighted that inconsistent adherence leads to poor sleep quality, excessive daytime sleepiness, and decreased productivity. 75.9% of respondents agreed that a once-nightly dose would be safer than twice-nightly formulations.
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in the Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. Interested parties can access a live webcast of the discussion through Avadel's Investor Relations website at investors.avadel.com, where the recording will remain available for 90 days after the conference.
Avadel Pharmaceuticals reported strong Q3 2024 results with $50.0 million in net revenue from LUMRYZ sales. The company reached 2,300 patients on LUMRYZ by September 30th, adding 700 new patients in Q3. Key developments include FDA approval for LUMRYZ in patients 7 years and older with narcolepsy, granted Orphan Drug Exclusivity through October 2031. The company reported a minimal operating loss of $0.3 million and a net loss of $2.6 million ($0.03 per share). Cash position stood at $65.8 million as of September 30, 2024.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced it will host a conference call and live webcast on November 12, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and provide a corporate update. The conference call can be accessed by dialing (800) 579-2543 with conference ID AVADEL. A live webcast will be available on the company's investor relations website, and a replay will be archived for 90 days.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced a favorable U.S. District Court ruling upholding the FDA's approval of LUMRYZ, the first once-at-bedtime oxybate treatment for narcolepsy. The Court ruled against Jazz Pharmaceuticals' challenge under the Administrative Procedure Act, confirming LUMRYZ's clinical superiority to Jazz's twice-nightly oxybate products. The decision maintains LUMRYZ's Orphan Drug Exclusivity granted in May 2023 and validates its unique dosing schedule as a significant advancement in patient care.
Avadel Pharmaceuticals (AVDL) and nference published real-world data in Sleep Advances analyzing demographic characteristics and comorbidities in narcolepsy patients. The study, based on electronic health data from over 2,000 narcolepsy patients and 2,000 matched controls through Mayo Clinic Platform, revealed that people with narcolepsy were more likely to have psychiatric, sleep, and pain disorders. Unlike previous claims-based studies, cardiovascular disease was not among the top 20 comorbidities. This marks the first real-world study in narcolepsy using aggregate electronic health record data.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced FDA approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older. LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for this condition, granted Orphan Drug Exclusivity for pediatric narcolepsy patients through October 16, 2031.
This approval expands LUMRYZ's use to the pediatric population, offering a single bedtime dose option. Narcolepsy affects about 1 in 2,000 people in the US, with 5% under 18. LUMRYZ was first approved for adult narcolepsy patients on May 1, 2023. The drug carries a boxed warning as a CNS depressant with potential for abuse and is available only through a restricted REMS program.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced the publication of a post-hoc analysis from their Phase 3 REST-ON clinical trial for LUMRYZ (sodium oxybate) in treating narcolepsy. The study, published in Sleep Medicine, showed that LUMRYZ significantly improved wakefulness, overall condition, weekly cataplexy episodes, and excessive daytime sleepiness compared to placebo, regardless of concomitant use of alerting agents.
The analysis involved 119 participants (63%) taking alerting agents and 71 (37%) not taking them. Significant improvements were observed with LUMRYZ at all doses versus placebo for Maintenance of Wakefulness Test (MWT), Clinical Global Impression-Improvement (CGI-I) rating, and weekly cataplexy episodes (p<0.05). The Epworth Sleepiness Scale (ESS) also showed significant improvements in both groups.
These findings highlight that alerting agents alone may be insufficient for treating excessive daytime sleepiness in narcolepsy patients, and LUMRYZ could be an effective treatment option, either as monotherapy or in combination with alerting agents.